Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 2/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25402578 | 0.89 | PDE4D (0.35) | PDE4DPDE3ASLC29A1POLA1 | |
| SCHEMBL26120946 | 0.85 | DUT (0.40) | TYMP | |
| SCHEMBL17384712 | 0.84 | PDE4D (0.34) | PDE4DPDE3ASLC29A1POLA1 | |
| SCHEMBL25401458 | 0.79 | CACNA1F (0.31) | PDE3A | |
| SCHEMBL25398163 | 0.76 | ALDH1A1 (0.30) | — | |
| SCHEMBL25400032 | 0.74 | DUT (0.38) | — | |
| SCHEMBL26127108 | 0.74 | DUT (0.38) | — | |
| SCHEMBL4074704 | 0.73 | TYMP (0.33) | TYMP | |
| SCHEMBL16144282 | 0.73 | PDE4D (0.34) | PDE4DPDE3ASLC29A1POLA1TYMP | |
| SCHEMBL16144281 | 0.72 | PDE3A (0.36) | PDE4DPDE3ASLC29A1POLA1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | PDE4D 1651/4885PDE3A 1349/4885SLC29A1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.